WSE:GEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland.


Snowflake Analysis

Flawless balance sheet with solid track record.

Share Price & News

How has Genomed Spólka Akcyjna's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.5%

GEN

-1.1%

PL Biotechs

4.6%

PL Market


1 Year Return

33.6%

GEN

62.1%

PL Biotechs

-18.6%

PL Market

Return vs Industry: GEN underperformed the Polish Biotechs industry which returned 60.4% over the past year.

Return vs Market: GEN exceeded the Polish Market which returned -19.4% over the past year.


Shareholder returns

GENIndustryMarket
7 Day-6.5%-1.1%4.6%
30 Day-19.7%7.1%5.6%
90 Day7.5%60.2%-6.7%
1 Year39.1%33.6%62.5%62.1%-16.6%-18.6%
3 Year56.2%50.1%22.9%22.7%-21.6%-27.0%
5 Year204.3%192.4%-6.2%-8.2%-18.2%-28.1%

Price Volatility Vs. Market

How volatile is Genomed Spólka Akcyjna's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Genomed Spólka Akcyjna undervalued compared to its fair value and its price relative to the market?

33.91x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GEN (PLN28.6) is trading above our estimate of fair value (PLN6.32)

Significantly Below Fair Value: GEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GEN is poor value based on its PE Ratio (33.9x) compared to the Biotechs industry average (33.8x).

PE vs Market: GEN is poor value based on its PE Ratio (33.9x) compared to the Polish market (10.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GEN is good value based on its PB Ratio (5.3x) compared to the PL Biotechs industry average (5.3x).


Next Steps

Future Growth

How is Genomed Spólka Akcyjna forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genomed Spólka Akcyjna has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Genomed Spólka Akcyjna performed over the past 5 years?

34.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GEN has high quality earnings.

Growing Profit Margin: GEN's current net profit margins (5.7%) are higher than last year (3.5%).


Past Earnings Growth Analysis

Earnings Trend: GEN has become profitable over the past 5 years, growing earnings by 34.2% per year.

Accelerating Growth: GEN's earnings growth over the past year (70.3%) exceeds its 5-year average (34.2% per year).

Earnings vs Industry: GEN earnings growth over the past year (70.3%) exceeded the Biotechs industry 17.1%.


Return on Equity

High ROE: GEN's Return on Equity (15.7%) is considered low.


Next Steps

Financial Health

How is Genomed Spólka Akcyjna's financial position?


Financial Position Analysis

Short Term Liabilities: GEN's short term assets (PLN6.2M) exceed its short term liabilities (PLN1.2M).

Long Term Liabilities: GEN's short term assets (PLN6.2M) exceed its long term liabilities (PLN176.7K).


Debt to Equity History and Analysis

Debt Level: GEN is debt free.

Reducing Debt: GEN has not had any debt for past 5 years.

Debt Coverage: GEN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GEN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Genomed Spólka Akcyjna's current dividend yield, its reliability and sustainability?

3.50%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: GEN's dividend (3.5%) is higher than the bottom 25% of dividend payers in the Polish market (2.24%).

High Dividend: GEN's dividend (3.5%) is low compared to the top 25% of dividend payers in the Polish market (6.95%).


Stability and Growth of Payments

Stable Dividend: Too early to tell whether GEN's dividend payments have been stable as they only just started paying a dividend.

Growing Dividend: Too early to tell if GEN's dividend payments are increasing as they only just started paying a dividend.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (118.6%), GEN's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Anna Boguszewska-Chachulska

no data

Tenure

Dr. Hab. Anna Boguszewska-Chachulska, Ph.D. is a Co-founder of Genomed Spólka Akcyjna and has been its Chief Executive Officer since 2013. Dr. Hab. Boguszewska-Chachulska also serves as President of the Ma ...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Genomed Spólka Akcyjna's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genomed Spólka Akcyjna
  • Ticker: GEN
  • Exchange: WSE
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: zł37.789m
  • Shares outstanding: 1.32m
  • Website: https://www.genomed.pl

Location

  • Genomed Spólka Akcyjna
  • ul. Ponczowa 12
  • Warsaw
  • 02-971
  • Poland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GENWSE (Warsaw Stock Exchange)YesBearer SharesPLPLNMay 2011

Biography

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers analysis of mutations responsible for congenital diseases in approximately 120 genes; and next generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, or bacteria and yeast genomes; and next generation sequencing and genetic counseling services. Further, the company offers DNA oligonucleotides synthesis, RNA oligonucleotides and peptide synthesis, various nucleotide modifications, and the 4LAB automated pipetting workstation, as well as laboratory equipment through the eStore. It serves scientific institutes, universities, hospitals, and biotechnological and pharmaceutical companies, as well as healthcare networks and individual customers. Genomed Spólka Akcyjna is based in Warsaw, Poland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/01 23:44
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.